A federal trial judge has approved the national settlement of a multidistrict litigation class action alleging that the generic version of the popular antidepressant drug Wellbutrin was not as therapeutically effective as the brand-name drug. He also took a shot at a landmark U.S. Supreme Court decision in the process.
The drugmakers agreed to give injunctive relief to the class by changing their product labels and taking other measures that the plaintiffs say will protect consumers. A total of $4.5 million in attorney fees and class counsel costs also was approved.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
